3 US Stocks Estimated To Be Trading At Up To 46.6% Discount
In This Article:
As the U.S. stock market navigates the complexities of inflation and employment data, investors are increasingly attentive to economic indicators that influence Federal Reserve policies and interest rate decisions. Amidst this cautious environment, identifying undervalued stocks can provide opportunities for those looking to capitalize on potential market mispricings.
Top 10 Undervalued Stocks Based On Cash Flows In The United States
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| MidWestOne Financial Group (NasdaqGS:MOFG) | $27.21 | $53.57 | 49.2% |
| Western Alliance Bancorporation (NYSE:WAL) | $85.43 | $169.30 | 49.5% |
| Cadence Bank (NYSE:CADE) | $31.17 | $61.27 | 49.1% |
| Heartland Financial USA (NasdaqGS:HTLF) | $57.04 | $110.18 | 48.2% |
| EVERTEC (NYSE:EVTC) | $32.96 | $65.85 | 49.9% |
| Bowhead Specialty Holdings (NYSE:BOW) | $28.44 | $56.14 | 49.3% |
| Shoals Technologies Group (NasdaqGM:SHLS) | $5.15 | $10.25 | 49.8% |
| Vertex Pharmaceuticals (NasdaqGS:VRTX) | $476.15 | $937.83 | 49.2% |
| SunOpta (NasdaqGS:STKL) | $6.36 | $12.65 | 49.7% |
| Viking Holdings (NYSE:VIK) | $37.84 | $74.69 | 49.3% |
We'll examine a selection from our screener results.
Celsius Holdings
Overview: Celsius Holdings, Inc. is a company that develops, processes, markets, distributes, and sells functional energy drinks and liquid supplements across various international markets with a market cap of $7.11 billion.
Operations: The company's revenue comes from its non-alcoholic beverages segment, totaling $1.49 billion.
Estimated Discount To Fair Value: 19%
Celsius Holdings appears undervalued based on cash flows, trading at US$34.91, below its estimated fair value of US$43.1. Recent earnings show strong growth with Q2 sales reaching US$401.98 million and net income at US$79.78 million, reflecting significant year-over-year increases. While profit growth is projected at 16.7% annually—outpacing the broader U.S. market—revenue growth is anticipated to be slower than 20% per year but faster than the market average of 8.8%.
Alnylam Pharmaceuticals
Overview: Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company that specializes in the discovery, development, and commercialization of novel therapeutics using ribonucleic acid interference technology, with a market cap of approximately $34.78 billion.
Operations: The company's revenue segment primarily comprises $2.34 billion from the discovery, development, and commercialization of RNAi therapeutics.